Manal F. Abdelmalek
YOU?
Author Swipe
View article: Efficacy and Safety of GLP-1 Receptor Agonists in MASH with Fibrosis: A Systematic Review and Meta-Analysis
Efficacy and Safety of GLP-1 Receptor Agonists in MASH with Fibrosis: A Systematic Review and Meta-Analysis Open
View article: Gastric Perforation Secondary to Acute Gastric Dilatation Without an Eating Disorder: A Case Report
Gastric Perforation Secondary to Acute Gastric Dilatation Without an Eating Disorder: A Case Report Open
View article: Elevated Homocysteine is Associated With Liver Fibrosis in Metabolic Dysfunction–Associated Steatotic Liver Disease in a Sex- and Menopause-Specific Manner
Elevated Homocysteine is Associated With Liver Fibrosis in Metabolic Dysfunction–Associated Steatotic Liver Disease in a Sex- and Menopause-Specific Manner Open
View article: Age-specific protective effects of statins against cirrhosis in patients with chronic liver enzyme elevation associated with metabolic dysfunction: a retrospective cohort study of electronic health records
Age-specific protective effects of statins against cirrhosis in patients with chronic liver enzyme elevation associated with metabolic dysfunction: a retrospective cohort study of electronic health records Open
The Department of Defence, Translational Team Science Award.
View article: <b>Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) in People with Diabetes: The Need for Screening and Early Intervention.</b><b> </b><b>A Consensus Statement of the American Diabetes Association.</b>
<b>Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) in People with Diabetes: The Need for Screening and Early Intervention.</b><b> </b><b>A Consensus Statement of the American Diabetes Association.</b> Open
Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly nonalcoholic fatty liver disease (NAFLD), is a growing but often unrecognized medical problem for people with diabetes (particularly type 2 diabetes). Liver health …
View article: Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) in People With Diabetes: The Need for Screening and Early Intervention. A Consensus Report of the American Diabetes Association
Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) in People With Diabetes: The Need for Screening and Early Intervention. A Consensus Report of the American Diabetes Association Open
Metabolic dysfunction–associated steatotic liver disease (MASLD), formerly referred to as nonalcoholic fatty liver disease (NAFLD), is a growing but often unrecognized medical problem for people with diabetes (particularly type 2 diabetes,…
View article: <b>Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) in People with Diabetes: The Need for Screening and Early Intervention.</b><b> </b><b>A Consensus Statement of the American Diabetes Association.</b>
<b>Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) in People with Diabetes: The Need for Screening and Early Intervention.</b><b> </b><b>A Consensus Statement of the American Diabetes Association.</b> Open
Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly nonalcoholic fatty liver disease (NAFLD), is a growing but often unrecognized medical problem for people with diabetes (particularly type 2 diabetes). Liver health …
View article: Author Correction: Targeting senescent hepatocytes for treatment of metabolic dysfunction-associated steatotic liver disease and multi-organ dysfunction
Author Correction: Targeting senescent hepatocytes for treatment of metabolic dysfunction-associated steatotic liver disease and multi-organ dysfunction Open
View article: Targeting senescent hepatocytes for treatment of metabolic dysfunction-associated steatotic liver disease and multi-organ dysfunction
Targeting senescent hepatocytes for treatment of metabolic dysfunction-associated steatotic liver disease and multi-organ dysfunction Open
View article: Altered liver sinusoidal endothelial cells in MASLD and their evolution following lanifibranor treatment
Altered liver sinusoidal endothelial cells in MASLD and their evolution following lanifibranor treatment Open
View article: Osteopontin Promotes Cholangiocyte Secretion of Chemokines to Support Macrophage Recruitment and Fibrosis in <scp>MASH</scp>
Osteopontin Promotes Cholangiocyte Secretion of Chemokines to Support Macrophage Recruitment and Fibrosis in <span>MASH</span> Open
Background and Aims Osteopontin (OPN) promotes the ductular reaction and is a major driver of chronic liver disease (CLD) progression. Although CLD is characterised by the accumulation of inflammatory cells including macrophages around the…
View article: An Infiltrative Case of Angiosarcoma Causing Portal Hypertension
An Infiltrative Case of Angiosarcoma Causing Portal Hypertension Open
Hepatic angiosarcoma is a rare and aggressive liver tumor. We report a case study of an 82-year-old elderly gentleman who presented with failure to thrive and ascites. Initially suspected to be cirrhosis, biopsy results eventually conclude…
View article: Lower hepatic <i>CBS</i> and <i>PEMT</i> expression in advanced NAFLD: inferencing strategies to lower homocysteine with a mathematical model
Lower hepatic <i>CBS</i> and <i>PEMT</i> expression in advanced NAFLD: inferencing strategies to lower homocysteine with a mathematical model Open
Aim: Hepatic homocysteine (Hcy) accumulation promotes inflammation and fibrosis in experimental nonalcoholic fatty liver disease (NAFLD), while vitamin B12 and folate reduce hepatic Hcy and protect animals from nonalcoholic steatohepatitis…
View article: The pan-PPAR agonist lanifibranor improves cardiometabolic health in patients with metabolic dysfunction-associated steatohepatitis
The pan-PPAR agonist lanifibranor improves cardiometabolic health in patients with metabolic dysfunction-associated steatohepatitis Open
Lanifibranor, a pan-PPAR agonist, improves liver histology in patients with metabolic dysfunction-associated steatohepatitis (MASH), who have poor cardiometabolic health (CMH) and cardiovascular events as major mortality cause. NATIVE tria…
View article: Alterations in zonal distribution and plasma membrane localization of hepatocyte bile acid transporters in patients with NAFLD
Alterations in zonal distribution and plasma membrane localization of hepatocyte bile acid transporters in patients with NAFLD Open
Background: NAFLD is highly prevalent with limited treatment options. Bile acids (BAs) increase in the systemic circulation and liver during NAFLD progression. Changes in plasma membrane localization and zonal distribution of BA transporte…
View article: A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis Open
Both the 80-mg dose and the 100-mg dose of resmetirom were superior to placebo with respect to NASH resolution and improvement in liver fibrosis by at least one stage. (Funded by Madrigal Pharmaceuticals; MAESTRO-NASH ClinicalTrials.gov nu…
View article: Phase 2, open-label, rollover study of cenicriviroc for liver fibrosis associated with metabolic dysfunction–associated steatohepatitis
Phase 2, open-label, rollover study of cenicriviroc for liver fibrosis associated with metabolic dysfunction–associated steatohepatitis Open
Background: Cenicriviroc (CVC) is a novel, orally administered antagonist of chemokine receptor types 2/5 that has demonstrated antifibrotic activity in a phase 2b study of patients with NASH. This phase 2, open-label, rollover study inves…
View article: Contents
Contents Open
View article: AHRR Hypomethylation mediates the association between maternal smoking and metabolic profiles in children
AHRR Hypomethylation mediates the association between maternal smoking and metabolic profiles in children Open
Background: Tobacco smoking during pregnancy is associated with metabolic dysfunction in children, but mechanistic insights remain limited. Hypomethylation of cg05575921 in the aryl hydrocarbon receptor repressor ( AHRR ) gene is associate…
View article: A randomized, double-blind, placebo-controlled trial of aldafermin in patients with NASH and compensated cirrhosis
A randomized, double-blind, placebo-controlled trial of aldafermin in patients with NASH and compensated cirrhosis Open
Background and Aims: Aldafermin, an engineered analog of the human hormone FGF19, improves liver histology in patients with noncirrhotic NASH; however, its efficacy and safety in compensated cirrhosis is unknown. No drug has yet to demonst…
View article: AGA Clinical Practice Update on the Role of Noninvasive Biomarkers in the Evaluation and Management of Nonalcoholic Fatty Liver Disease: Expert Review
AGA Clinical Practice Update on the Role of Noninvasive Biomarkers in the Evaluation and Management of Nonalcoholic Fatty Liver Disease: Expert Review Open
View article: Serum Metabolites Are Associated With HFpEF in Biopsy‐Proven Nonalcoholic Fatty Liver Disease
Serum Metabolites Are Associated With HFpEF in Biopsy‐Proven Nonalcoholic Fatty Liver Disease Open
Background Nonalcoholic fatty liver disease (NAFLD) and heart failure with preserved ejection fraction (HFpEF) share common risk factors, including obesity and diabetes. They are also thought to be mechanistically linked. The aim of this s…
View article: A multisociety Delphi consensus statement on new fatty liver disease nomenclature
A multisociety Delphi consensus statement on new fatty liver disease nomenclature Open
View article: Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH
Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH Open
In this phase 2b trial, treatment with pegozafermin led to improvements in fibrosis. These results support the advancement of pegozafermin into phase 3 development. (Funded by 89bio; ENLIVEN ClinicalTrials.gov number, NCT04929483.).
View article: A multisociety Delphi consensus statement on new fatty liver disease nomenclature
A multisociety Delphi consensus statement on new fatty liver disease nomenclature Open
View article: A multisociety Delphi consensus statement on new fatty liver disease nomenclature
A multisociety Delphi consensus statement on new fatty liver disease nomenclature Open
The principal limitations of the terms NAFLD and NASH are the reliance on exclusionary confounder terms and the use of potentially stigmatising language. This study set out to determine if content experts and patient advocates were in favo…
View article: Longer Breastfeeding Duration Is Associated With Decreased Risk of Hepatic Fibrosis Among Young Women With Nonalcoholic Fatty Liver Disease
Longer Breastfeeding Duration Is Associated With Decreased Risk of Hepatic Fibrosis Among Young Women With Nonalcoholic Fatty Liver Disease Open
Breastfeeding is widely recognized to exert various health benefits in infants and mothers (reviewed by Victora et al1Victora C.G. et al.Lancet. 2016; 387: 475-490Abstract Full Text Full Text PDF PubMed Scopus (3675) Google Scholar). Mothe…
View article: Pembrolizumab in combination with epigenetic therapy is safe and active in heavily treated patients with peripheral T‐cell lymphoma and cutaneous T‐cell lymphoma
Pembrolizumab in combination with epigenetic therapy is safe and active in heavily treated patients with peripheral T‐cell lymphoma and cutaneous T‐cell lymphoma Open
Introduction: Peripheral T-cell lymphomas are uniquely sensitive to epigenetic modifiers. We have shown that decitabine and 5-azacytidine (Marchi et al.; Br. J. Haematol. 171; 2015) induce the expression of cancer testis antigens in pre-cl…
View article: Tropifexor plus cenicriviroc combination versus monotherapy in nonalcoholic steatohepatitis: Results from the phase 2b TANDEM study
Tropifexor plus cenicriviroc combination versus monotherapy in nonalcoholic steatohepatitis: Results from the phase 2b TANDEM study Open
Background and Aims: With distinct mechanisms of action, the combination of tropifexor (TXR) and cenicriviroc (CVC) may provide an effective treatment for NASH. This randomized, multicenter, double-blind, phase 2b study assessed the safety…
View article: Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Stage 3 Fibrosis (FALCON 1): A Randomized Phase 2b Study
Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Stage 3 Fibrosis (FALCON 1): A Randomized Phase 2b Study Open
The FALCON 1 study did not meet its primary endpoint; a ≥1-point decrease in fibrosis score without NASH worsening or NASH improvement without fibrosis worsening assessed via biopsy. Pegbelfermin was generally well tolerated during 48 week…